|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...29303132333435363738394041» |
- ||||||| Lemtrada (alemtuzumab) / Sanofi
Trial completion: CARE-MS II: Comparison of Alemtuzumab and Rebif (clinicaltrials.gov) - Jan 29, 2012
P3, N=840, Completed, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed
- baminercept (BG 9924) / Biogen
Enrollment change: Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS) (clinicaltrials.gov) - Jan 25, 2012
P1/2, N=0, Withdrawn, Sponsor: Biogen Idec
Active, not recruiting --> Completed N=80 --> 0
- ||| Avonex (recombinant IFN-β-1a) / Biogen
Trial completion, Compliance: COMPASS: COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS (clinicaltrials.gov) - Jan 25, 2012
P=N/A, N=1000, Completed, Sponsor: Biogen Idec
N=80 --> 0 Active, not recruiting --> Completed
- ||| dexpramipexole (KNS-760704) / Knopp Biosciences, Biogen
Trial completion: Dexpramipexole SAD/MAD Study (clinicaltrials.gov) - Jan 25, 2012
P1, N=63, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | dexpramipexole (KNS-760704) / Knopp Biosciences, Biogen
Trial completion: Dexpramipexole Renal PK Study (clinicaltrials.gov) - Jan 25, 2012
P1, N=36, Completed, Sponsor: Biogen Idec
Not yet recruiting --> Completed Recruiting --> Completed
- New P2 trial: Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients (clinicaltrials.gov) - Jan 23, 2012
P2, N=50, Recruiting, Sponsor: Health Sciences Centre, Winnipeg, Manitoba
- | otilimab (GSK3196165) / GSK
New P1/2 trial: Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis (clinicaltrials.gov) - Jan 23, 2012
P1/2, N=30, Completed, Sponsor: MorphoSys AG
- Enrollment open: Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis (clinicaltrials.gov) - Jan 23, 2012
P1, N=60, Recruiting, Sponsor: Portland VA Medical Center
Recruiting --> Completed Not yet recruiting --> Recruiting
- Trimesta (estriol oral) / Synthetic Biologics
Enrollment closed: A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jan 22, 2012
P2, N=150, Active, not recruiting, Sponsor: University of California, Los Angeles
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion: American Ginseng Treatment for Multiple Sclerosis Related Fatigue (clinicaltrials.gov) - Jan 22, 2012
P2, N=56, Completed, Sponsor: Oregon Health and Science University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Rebif (human IFN-β-1a) / EMD Serono
New P2 trial: EMR200136-549: Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a (clinicaltrials.gov) - Jan 19, 2012
P2, N=80, Recruiting, Sponsor: Merck KGaA
- ||||| Lemtrada (alemtuzumab) / Sanofi
Enrollment closed: An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab (clinicaltrials.gov) - Jan 19, 2012
P3, N=1322, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- ||||||| Trial completion, HEOR: Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients (clinicaltrials.gov) - Jan 18, 2012
P3, N=2417, Completed, Sponsor: Novartis
Enrolling by invitation --> Active, not recruiting Recruiting --> Completed
- ||| dexpramipexole (KNS-760704) / Knopp Biosciences, Biogen
New P1 trial: Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate) (clinicaltrials.gov) - Jan 16, 2012
P1, N=68, Completed, Sponsor: Biogen Idec
- ||| Enrollment change: Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis (clinicaltrials.gov) - Jan 9, 2012
P2, N=182, Completed, Sponsor: Sanofi
Recruiting --> Completed N=241 --> 182
- New P2 trial: Pacing Activity Self-management for Patients With Multiple Sclerosis (clinicaltrials.gov) - Jan 9, 2012
P2, N=50, Recruiting, Sponsor: Vrije Universiteit Brussel
- Trial initiation date, Adverse events: Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis (clinicaltrials.gov) - Jan 4, 2012
P1/2, N=22, Completed, Sponsor: Royan Institute
N=241 --> 182 Initiation date: Jul 2011 --> Dec 2011
- ||| Avonex (recombinant IFN-?-1a) / Biogen
New P1 trial: Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers (clinicaltrials.gov) - Dec 26, 2011
P1, N=110, Completed, Sponsor: Biogen Idec
- ||||| Tysabri (natalizumab) / Biogen, Royalty
New P4 trial: TOFIINGO: Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod (clinicaltrials.gov) - Dec 22, 2011
P4, N=158, Completed, Sponsor: Novartis Pharmaceuticals
- ||||| New P4 trial: EARLiMS: Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy (clinicaltrials.gov) - Dec 22, 2011
P4, N=434, Recruiting, Sponsor: Novartis Pharmaceuticals
- |||||||||| New P3 trial: Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Dec 20, 2011
P3, N=161, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- Betaseron (IFN-?-1b) / Bayer
Enrollment change: Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis (clinicaltrials.gov) - Dec 20, 2011
P=N/A, N=50, Active, not recruiting, Sponsor: Bayer
Initiation date: Jul 2011 --> Dec 2011 N=100 --> 50
- New P4 trial: PRISS: Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis (clinicaltrials.gov) - Dec 19, 2011
P4, N=32, Not yet recruiting, Sponsor: University of Michigan
- Nerventra (laquinimod) / Active Biotech, Rebif (human IFN-?-1a) / EMD Serono
Trial initiation date: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability (clinicaltrials.gov) - Dec 14, 2011
P2, N=0, Withdrawn, Sponsor: Teva Pharmaceutical Industries
N=100 --> 50 Initiation date: Jul 2011 --> Mar 2012
- | Radicava (edaravone) / Mitsubishi Tanabe
Enrollment change: Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III (clinicaltrials.gov) - Dec 13, 2011
P3, N=25, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Initiation date: Jul 2011 --> Mar 2012 N=20 --> 25
- |||||||||| Radicava (edaravone) / Mitsubishi Tanabe
New P3 trial: Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Dec 13, 2011
P3, N=128, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- Enrollment open, IO biomarker: Nanotechnology for Detection of Multiple Sclerosis Compared to Autoimmune and Neurological Diseases by Exhaled Samples (clinicaltrials.gov) - Dec 12, 2011
P1, N=400, Recruiting, Sponsor: Carmel Medical Center
N=20 --> 25 Not yet recruiting --> Recruiting
- ||||| New P4 trial: Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Dec 11, 2011
P4, N=178, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- Biomarker, Enrollment closed: BIO_ALS-01: Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Dec 11, 2011
P=N/A, N=475, Active, not recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| glatiramer acetate / Generic mfg.
New P3 trial: Efficacy and Safety of GTR in Comparison to Copaxone® (clinicaltrials.gov) - Dec 7, 2011
P3, N=750, Active, not recruiting, Sponsor: Synthon BV
- |||| Tysabri (natalizumab) / Biogen
Clinical: RESTORE: Treatment Interruption of Natalizumab (clinicaltrials.gov) - Dec 7, 2011
P2, N=175, Completed, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Tysabri (natalizumab) / Biogen, Royalty
Enrollment open: STRIVE: Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants (clinicaltrials.gov) - Dec 7, 2011
P=N/A, N=0, Recruiting, Sponsor: Biogen Idec
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) (clinicaltrials.gov) - Dec 7, 2011
P1, N=76, Completed, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| teriflunomide / Generic mfg.
New P2 trial: Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses (clinicaltrials.gov) - Dec 5, 2011
P2, N=179, Completed, Sponsor: Sanofi
- paquinimod (ABR-215757) / Active Biotech
Biomarker, New P2 trial: An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod) (clinicaltrials.gov) - Dec 5, 2011
P2, N=9, Completed, Sponsor: Active Biotech AB
- | telbermin (sNN-0029) / Newron
Trial completion: A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Dec 4, 2011
P1/2, N=18, Completed, Sponsor: NeuroNova AB
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc) (clinicaltrials.gov) - Nov 29, 2011
P=N/A, N=490, Terminated, Sponsor: Actelion
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- ||||| dalfampridine / Generic mfg.
New P4 trial, HEOR: ENABLE: Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis (clinicaltrials.gov) - Nov 24, 2011
P4, N=800, Active, not recruiting, Sponsor: Biogen Idec
- ||| Mayzent (siponimod) / Novartis
Enrollment closed: Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Nov 22, 2011
P2, N=186, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Terminated Enrolling by invitation --> Active, not recruiting
- ||| Omigapil (SNT-317) / Santhera
Enrollment change: A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS) (clinicaltrials.gov) - Nov 21, 2011
P2, N=350, Completed, Sponsor: Novartis
Enrolling by invitation --> Active, not recruiting N=500 --> 350
- DB105 / Denovo, J&J
Trial termination: REINO: Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon (clinicaltrials.gov) - Nov 21, 2011
P2a, N=15, Terminated, Sponsor: Orion Corporation, Orion Pharma
N=500 --> 350 Recruiting --> Terminated; Recommendation by study DSMC to the sponsor following interim analysis of 8 subjects.
- Trial termination: Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Nov 16, 2011
P3, N=1, Terminated, Sponsor: Johns Hopkins University
Recruiting --> Terminated; Recommendation by study DSMC to the sponsor following interim analysis of 8 subjects. Recruiting --> Terminated
- Enrollment change: Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Nov 16, 2011
P3, N=1, Terminated, Sponsor: Johns Hopkins University
Recruiting --> Terminated N=15 --> 1
- || Opsumit (macitentan) / Nippon Shinyaku, J&J
New P3 trial: DUAL-2: Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients (clinicaltrials.gov) - Nov 16, 2011
P3, N=265, Terminated, Sponsor: Actelion
- |||||||||| Opsumit (macitentan) / Nippon Shinyaku, J&J
New P3 trial: DUAL-1: Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients (clinicaltrials.gov) - Nov 16, 2011
P3, N=289, Completed, Sponsor: Actelion
- ||||| Enrollment change: Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Nov 15, 2011
P3, N=920, Completed, Sponsor: Novartis
N=15 --> 1 N=1250 --> 920
- ||||||| Trial completion: Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Nov 15, 2011
P3, N=920, Completed, Sponsor: Novartis
N=1250 --> 920 Active, not recruiting --> Completed
- | firategrast (SB683699) / GSK
Trial completion: Healthy Volunteer Study Using 3 Different Formulations of Firategrast (clinicaltrials.gov) - Nov 13, 2011
P1, N=38, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Completed
- ||| ozanezumab (GSK 1223249) / GSK
Trial completion, IO biomarker: First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Nov 13, 2011
P1, N=76, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Betaseron (IFN-β-1b) / Bayer
Trial completion: Physical Disability in Patients Treated With Betaferon (clinicaltrials.gov) - Nov 9, 2011
P=N/A, N=83, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Recruiting --> Completed